Monthly Archives: July 2016

SHAREHOLDER ALERT – Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Inovalon Holdings, Inc. (INOV) and Lead Plaintiff Deadline August 23, 2016

NEW YORK, NY / ACCESSWIRE / July 20, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District, Southern District of New York, on behalf of those who purchased shares of Inovalon Holdings, Inc. (“Inovalon” or the “Company”) (NASDAQ: INOV), pursuant or traceable to the Registration Statement and Prospectus (collectively, the “Registration Statement”) issued in connection with Inovalon’s February 12, 2015 initial public offering (“IPO”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.

Inovalon is a technology company based in Bowie, Maryland. It uses cloud-based analytics and technology to help clients achieve insights that approve clinical and quality outcomes, utilization and financial performance in the healthcare industry.

In February, 2015, Inovalon issued over 25 million shares of its common stock for $27 per share, raising over $684 million in gross proceeds.

The complaint alleges that the Registration Statement released in connection with the IPO contained falsified statements and omitted to state material facts required by governing regulations and necessary for investors to make an informed decision. Defendants failed to disclose that Inovalon makes a large percentage of its revenue from sales in the City of New York and the State of New York, both of which were restructuring their corporate tax schemes in order to capture more taxes from out-of-state businesses like Inovalon doing substantial business within their borders. The corporate tax rate increased, effective January 1, 2015, which was more than a month prior to Inovalon’s IPO, significantly inflated Inovalon’s effective tax rate, lowering its 2015 revenue potential. This information should have been included in the Registration Statement but were not. The Registration Statement claimed that Inovalon’s year-over-year “effective income tax rate…remained relatively stable at 39%.”

Once this information was made public, Inovalon stock dropped. At the time of the filing of the complaint, Inovalon shares were trading below $18 per share, or roughly 33% below the IPO price.

No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm’s site: http://www.bgandg.com/#!inov/kk5vc. You can also contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Inovalon, you have until August 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441681

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Halyard Health, Inc. (HYH) and Kimberly-Clark Corporation (KMB) & Lead Plaintiff Deadline: August 29, 2016

NEW YORK, NY / ACCESSWIRE / July 20, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Halyard Health, Inc. (“Halyard” or the “Company”) (NYSE: HYH) and Kimberly-Clark Corporation (“Kimberly-Clark” or the “Company”) (NYSE: KMB) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and is on behalf of a class consisting of all persons other than Defendants who: (1) purchased or acquired Kimberly-Clark securities on or after February 25, 2013 and consequently received Halyard shares pursuant to Kimberly-Clark’s spin-off of Halyard, effective as of October 31, 2014; and/or (2) purchased or acquired Halyard securities between October 21, 2014 and April 29, 2016, both dates inclusive (collectively, the “Class Period”).

This case seeks to recover damages caused by the Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder.

Halyard Health, formerly Kimberly-Clark Health Care is a global medical manufacturer based in Alpharetta, Georgia. The Company operates through two divisions, Surgical and Infection Prevention (S&IP), and Medical Devices.

Halyard was the Health Care operating segment of Kimberly-Clark before October of 2014. Kimberly-Clark manufactured personal care, consumer tissue, and professional products. On October 7, 2014, Kimberly-Clark revealed the details for the spin-off of its Health Care segment as Halyard Health, Inc., guiding investors that they would receive one share of Halyard Health stock for every eight shares of Kimberly-Clark stock held on October 23, 2014.

In late 2013, the Ebola virus outbreak began in Guinea and spread to Liberia, Sierra Leone, and other West African nations. In August 2014 the World Health Organization labeled the outbreak as a Public Health Emergency of International Concern, invoking legal measures on disease prevention, surveillance and control. On September 30, 2014, the United States Centers for Disease Control and Prevention announced the first case of Ebola virus in the United States.

As the Ebola epidemic grew, the demand for personal protective equipment like eye shields, face masks and disposable gowns grew. Kimberly-Clark’s Health Care segment and Halyard, manufactured the MICROCOOL surgical gowns.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Particularly, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s MICROCOOL surgical gowns constantly failed its tests to meet industry standards; (2) Kimberly-Clark and Halyard knew of the defects and still provided MICROCOOL surgical gowns to U.S. workers during the Ebola crisis; and (3) consequently, Defendants’ public statements were materially false and misleading at all relevant times.

On May 1, 2016, 60 Minutes announced that Kimberly-Clark and Halyard had knowledgeably provided faulty and unreliable surgical gowns to U.S. workers during the Ebola crisis. A Company insider stated that these MICROCOOL gowns would leak and did not meet the safety standards for Ebola, and still Kimberly-Clark and Halyard “aggressively” promoted and sold the MICROCOOL gowns to hospitals at the height of the Ebola epidemic.

Following this news, Halyard stock dropped $1.21, or 4.3%, to close at $26.95 per share on May 2, 2016.

A class action lawsuit has already been filed. If you have incurred a loss of over $100,000 and wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/#!hyhkmb/dtdqc or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Haylard and/or Kimberly-Clark you have until August 29, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441811

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Lipocine, Inc. (LPCN) and Lead Plaintiff Deadline August 30, 2016

NEW YORK, NY / ACCESSWIRE / July 20, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Lipocine, Inc. (“Lipocine” or the “Company”) (NASDAQ: LPCN) and certain of its officers. The class action was filed on behalf of a class consisting of all persons or entities who purchased Lipocine securities between June 30, 2015 through June 28, 2016, both dates inclusive (the “Class Period”).

The Complaint alleges that throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Lipocine’s filing of its New Drug Application to the U.S. Food and Drug Administration for LPCN 1021, Lipocine’s lead product candidate, contained deficiencies; and (2) consequentially, defendants’ statements about Lipocine’s business and operations were false and misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/#!lpcn/geg3g or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Lipocine you have until August 30, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442038

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action against Ambac Financial Group, Inc. (AMBC) & Lead Plaintiff Deadline August 29, 2016

NEW YORK, NY / ACCESSWIRE / July 20, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ambac Financial Group, Inc. (“Ambac” or the “Company”) (NASDAQ: AMBC) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, is on behalf of a class consisting of all persons or entities who purchased Ambac securities between November 13, 2013 through June 30, 2015, inclusive (the “Class Period”).

The Complaint alleges that throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Ambac had far greater losses and loss exposure to anticipated defaults than it had previously disclosed in its public finance bond portfolio; (2) Ambac’s credit risk surveillance strategies were insufficient; (3) Ambac was failing to implement mitigation strategies in a timely manner to stabilize the residual value of its financial guarantee business; (4) consequentially, Ambac’s financial condition was much worse than represented; and (5) Ambac failed to maintain adequate internal controls over financial reporting. Due to the defendants’ alleged false and misleading statements, Ambac’s stock traded at artificially inflated prices during the Class Period, and investors were damaged once the true details were made public.

According to the Complaint, on June 29, 2015, the governor of Puerto stated that the island’s debt of over $70 million was “not payable” and Puerto Rico would soon be unable to pay its upcoming interest payments. This declaration exposed Ambac’s potential liability of up to $2.5 billion of the Commonwealth’s debt it insures. Following this news, Ambac dropped $6.47 per share or 28.9%, on July 1, 2015.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/#!ambc/u06xx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Ambac you have until August 29, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442031

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Neovasc, Inc. (NVCN) and Lead Plaintiff Deadline – August 5, 2016

NEW YORK, NY / ACCESSWIRE / July 20, 2016 / Bronstein, Gewirtz & Grossman, LLC, notifies investors
of class action against of Neovasc, Inc. (“Neovasc” or “the Company”) (NASDAQ: NVCN). The class action has been filed on behalf of a class consisting of all persons or entities who purchased Neovasc securities during the period between January 26, 2015, and May 19, 2016, inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

Neovasc is a specialty medical company that develops cardiovascular products. Neovasc’s primary product is the Tiara, a transcatheter mitral valve device used to treat mitral valve disease. This device can be implanted through minimally invasive surgery to patients with mitral regurgitation resulting from mitral heart valve disease.

The Complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about Neovasc’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose: (1) Neovasc’s Tiara device was advanced through dishonest business practices, including the embezzlement of trade secrets from another company; (2) that there was a related and legitimate lawsuit against Neovasc regarding
the misappropriation of trades secrets; and (3) consequentially, Defendants’ statements about Neovasc’s business, operations, and prospects were materially false and misleading at relevant times. Following this information entering the market, investors suffered damages.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action, visit the firm’s website: http://www.bgandg.com/#!nvcn/m3197. To discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Neovasc you have until August 5, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441334

ReviewTrackers Secures $4 Million in Capital to Meet Enterprise Demand

CHICAGO, IL / ACCESSWIRE / July 20, 2016 / ReviewTrackers, the award-winning customer feedback platform, has successfully secured $4 million in growth capital, led by American Family Ventures. Square 1 bank, a division of Pacific Western Bank, provided a debt facility to complement this latest capital raise, bringing ReviewTrackers’ total financing to $6.1 million. With this latest round of financing, ReviewTrackers will accelerate the development of its software to meet the needs of its expanding enterprise-level customer base.

“We invest in companies that we believe can improve how businesses interact with and deliver value to customers,” said Dan Reed, managing director of American Family Ventures. “It’s essential for businesses in the digital age to become customer-centric and deliver on their brand promises. ReviewTrackers offers that function – a simple, fast, and easy way to listen, respond to, and innovate based on what customers are saying.”

Ross Mires, vice president, technology banking at Square 1 Bank commented on Square 1’s involvement by saying, “In today’s data-driven world, it is vital for businesses to not only understand their online reviews, but also utilize them to improve sales functions, customer service, and other operations. We are excited to partner with the ReviewTrackers’ team as they continue to bridge this information gap.”

Since taking initial capital from American Family Ventures in early 2014, ReviewTrackers has increased its revenue over 10x, tripled its workforce and grown its customer base to more than 25,000 business locations. Many of the newer features are not readily available within other customer feedback management platforms, helping ReviewTrackers to take the lead in innovation.

####

Contact:

Mandy Yoh
ReviewTrackers
Head of Communications
Email: mandy@reviewtrackers.com
Office: (866) 854-7670
http://www.reviewtrackers.com

About ReviewTrackers

ReviewTrackers is the award-winning software that elevates the voice of the customer and enables brands to innovate based on customer reviews and feedback. The platform aggregates reviews from over 70 review sites, helping busy professionals save time and focus on what matters most: their customers. ReviewTrackers’ easy-to-use dashboard helps brands quickly manage their online reviews, uncover hidden customer insights, make data-driven decisions and improve brand reputation. Used by over 25,000 businesses, ReviewTrackers is the premier customer feedback solution for enterprise businesses.

About American Family Insurance

Madison, Wis. – based American Family Insurance is the nation’s 13th-largest mutual property/casualty insurance group and ranks 332nd on the Fortune 500 list. The company sells American Family-brand products, including auto, homeowners, life, business and farm/ranch insurance, through its exclusive agents in 19 states. American Family affiliates (The General, Homesite and AssureStart) also provide options for consumers who want to manage their insurance matters directly over the Internet or by phone. Web www.amfam.com; Facebook www.facebook.com/amfam; Twitter www.twitter.com/amfam; Google+ plus.google.com/+amfam/.

About Square 1 Bank

Square 1 Bank is a division of Pacific Western Bank, a Los Angeles-based commercial bank with over $21 billion in assets. A full service financial services partner to entrepreneurs and their investors, Square 1 provides clients flexible resources and attentive service to help their companies grow. Square 1 offers a broad range of venture debt, treasury and cash management solutions through offices in top innovation centers: Atlanta, Austin, the Bay Area, Boston, Chicago, Denver, Durham, Los Angeles, Minneapolis, New York, San Diego, Seattle and Washington, DC. Pacific Western Bank is a wholly-owned subsidiary of PacWest Bancorp (NASDAQ:PACW). For more information, visit www.square1bank.com.

SOURCE: ReviewTrackers

ReleaseID: 442611

Thermalabs Exfoliating Mitt Scores Big In The Market

One of Thermalabs products, the exfoliating mitt, has recorded an incredible performance in the market.

Thermalabs Exfoliating Mitt Scores Big In The Market

New York, United States – July 20, 2016 /MarketersMedia/

Thermalabs exfoliating mitt has sold hundreds of thousands of units and garnered an average 5-star rating from scores of customers ever since it was launched some few months ago. This is certainly an extraordinary achievement for any new product. However, it’s not a first for Thermalabs. Many of the company’s earlier products, including the Glow2Go tan wipes and the Ultimitt tan applicator mitt, has won several accolades on Amazon.com and other major online retail marketplaces.

Thermalabs is a major cosmetics firm that’s based in the United States. The company is headquartered in New York City, but all the same operates a production facility in Israel’s Galilee region. Thermalabs started operations in 2013, inspired by a commitment to contribute to a skin-cancer free world. According to medical reports, millions of people were diagnosed with skin cancer each year. A hefty section of these cases could be attributed to exposing the skin to the sun, as a way of looking for a tan. By creating healthy alternatives to sun-tanning, Thermalabs was confident that it could make a profound difference. Following months of painstaking research that involved some big names in the skin care industry, the firm introduced a self-tanning lotion that delivered a beautiful tan within hours after being applied to the skin. The product was designed from highly organic and natural ingredients, including the likes of Aloe Vera, Green Tea, and Shea Butter. The product’s immense success helped set the stage for the company’s subsequent endeavors, and created a platform for the successful launch of Thermalabs upcoming products. Today, the company has contributed at least 16 different products to the global cosmetics industry. Most of these are top-quality tanners and tanning accessories.

Thermalabs exfoliating mitt was launched earlier this year. It’s an all-natural product that clears the skin of black spots, dead cells, and other contaminants. It helps get healthier and younger-looking skin with an even tone. The exfoliating can help fix tanning flaws such as blotches, residues, as well as color blemishes. The product is washable and lasts long. It ships with a printed guide that helps users understand how to optimally utilize it, as well as a free finger exfoliator for special detail areas such as the face.

Thermalabs Exfoliating Mitt has scored an average 5-star rating from over 150 customers on Amazon.com. Isnull, one of the users who bought and rated this product 5-star on global e-commerce marketplace Amazon.com, reviewed, “My wife loves this product. It really works. It gets the dead skin out and makes the skin much smoother. Easy to use. It comes with Finger Exfoliator which is very helpful to use in the small area and more sensitive area. The mitt has two sides, Pink for a lighter exfoliation or Black for a deeper one. Wet it before you use it. I would recommend it.”

For more information, please visit http://www.thermalabs.com/home

Contact Info:
Name: Jennifer Parker
Organization: Thermalabs

Video URL: https://www.youtube.com/watch?v=42AV0CHRRBk

Source: http://marketersmedia.com/thermalabs-exfoliating-mitt-scores-big-in-the-market/123965

Release ID: 123965

Post Earnings Coverage as Goldman Sachs Reports Strong Numbers

LONDON, UK / ACCESSWIRE / July 20, 2016 /Active Wall St. announces its post-earnings coverage on The Goldman Sachs Group Inc. (NYSE: GS). The company released its Q2 FY16 financial results on Tuesday, July 19, 2016. The investment bank that currently has $1.31 trillion in assets under supervision reported that quarterly earnings rose 74%, boosted from a sharp drop in legal costs and its shrinking bottom line. Register with us now for your free membership at:

http://www.activewallst.com/register/

Today, AWS is promoting its earnings coverage on GS. Get all of our free coverage by signing up to http://www.activewallst.com/registration-3/?symbol=GS.

Earnings Reviewed

For the period ending on June 30, 2016, Goldman’s reported net income of $1.82 billion, or $3.72 per share, higher than $1.05 billion, or $1.98 per share, in the year ago period. The sharp rise in earnings was attributed to a nearly $1.3 billion decline in “other expenses,” which consists of legal costs. For Q2 FY16, revenue declined 13% to $7.93 billion from $9.07 billion in Q2 FY15. Analysts estimated that the bank would earn $3 per share on revenue of $7.58 billion.

Banks Reporting Improves

The on-going earnings season has been a welcome breather for the beleaguered banks. JPMorgan Chase & Co. (NYSE: JPM) earnings on July 14, 2016, topped analysts’ estimates. On July 15, 2016, Wells Fargo & Co. (NYSE: WFC) matched earnings expectations, while Citigroup Inc. (NYSE: C) topped earnings estimate as well. On July 19, 2016, Bank of America Corp. (NYSE: BAC) also reported better-than-expected top and bottom line. Sign up now and get more on JPM: http://www.activewallst.com/registration-3/?symbol=JPM.

For Q2 FY16, Goldman’s investment banking business brought in $1.79 billion, from $2.02 billion in Q2 FY15 attributed to stronger-than-expected bond underwriting revenues and a healthy backlog of M&A deals. Goldman’s Investing & Lending segment, which comprises of private equity and other alternative investments, saw revenues decline to $1.1 billion, or 38%. Goldman’s investment management business reported revenue of $1.35 billion in Q2 FY16, down 18% from $1.65 billion in the year earlier quarter. Debt-underwriting revenue increased 20% to $724 million which Goldman stated was the division’s second- highest quarterly performance ever.

Goldman’s trading unit was the only division to post an increase in revenue as compared to Q2 FY15, bolstered by stronger-than-expected revenues from bond trading; Britain’s decision on June 24 to leave the European Union also provided a tailwind. The firm’s fixed income commodity and currency trading division posted a 20% rise in revenues to $1.93 billion, helping its overall trading unit to $3.68 billion in total revenues, a 2% increase; however the increase in trading revenue is lower than other major Wall Street’s banks – J.P. Morgan’s trading revenue gained 25% from Q2 FY15; Bank of America reported that its trading revenue advanced 19%; and Citigroup’s trading revenue grew 15%.

Goldman said that it reduced overall staffing by 5% in Q2 FY16. Also, compensation declined 13% to $3.3 billion in Q2 FY16 which Goldman attributed to a decrease in net revenue. Goldman’s return on equity, a closely watched measure of banks’ profitability, stood at 8.7% during Q2 FY16. While profit that was up from 4.8% in Q2 FY15, it is still way below the 20% the megabank regularly topped prior to the 2008-2009 financial crisis.

Share Repurchase and Guidance

Goldman Sachs’ board of directors of authorised a dividend of $0.65 per common share, payable on September 29, 2016 to common shareholders of record on September 1, 2016. During Q2 FY16, Goldman repurchased 11.1 million shares of its common stock at an average price of $156.60 per share, for a total cost of $1.74 billion.

Stock Performance

Goldman’s shares declined 1.18% to close July 19, 2016, trading session at $161.41, with 5.4 million shares changing hands. The bank’s stock has gained 10.83% in the past one month and 9.68% on an YTD basis as compared to S&P 500 which is up 7.14% during the same time frame.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 442606

Coverage Initiated on Select Canadian Basic Materials’ Stocks Agnico Eagle Mines, Agrium, First Quantum Minerals, and Goldcorp

LONDON, UK / ACCESSWIRE / July 20, 2016 / Active Wall St. announces the list of stocks for today’s coverage. Pre-market the Active Wall St. team provides the technical notes impacting selected stocks trading on the Toronto Exchange and belonging under the Basic Materials sector. Companies recently under review include Agnico Eagle Mines, Agrium, First Quantum Minerals, and Goldcorp. Get all of our research notes free by signing up at: http://www.activewallst.com/register/.

On Tuesday, July 19, 2016, the TSX Composite Index edged 0.05% lower, to finish at 14,524.61. Active Wall St. has initiated coverage on the following equities: Agnico Eagle Mines Ltd (TSX: AEM), Agrium Inc. (TSX: AGU), First Quantum Minerals Ltd (TSX: FM), and Goldcorp Inc. (TSX: G). Register with us now for your free membership and more at: http://www.activewallst.com/register/.

Agnico Eagle Mines Ltd (TSX: AEM)

Toronto, Canada headquartered Agnico Eagle Mines Ltd’s stock finished Tuesday’s session flat at $72.58 with a total volume of 564,044 shares traded. Over the last one month and the previous three months, Agnico Eagle Mines L td’s shares have surged 12.30% and 40.63%, respectively. Further, the Company’s stock has rallied 140.49% in the past one year. The Company’s shares are trading above its 50-day and 200-day moving averages. Agnico Eagle Mines Ltd’s 50-day moving average of $67.32 is above its 200-day moving average of $53.48. Shares of Agnico Eagle Mines Ltd, which engages in the exploration, development, and production of mineral properties in Canada, Finland, and Mexico, traded at a PE ratio of 665.87. See our notes on AEM.TO at: http://www.activewallst.com/registration-3/?symbol=AEM.

Agrium Inc. (TSX: AGU)

Calgary, Canada headquartered Agrium Inc.’s stock declined 1.99%, to close the day at $122.50. The stock recorded a trading volume of 328,182 shares, which was above its three months average volume of 308,190 shares. Shares of Agrium, which produces, markets, and distributes crop nutrients, crop protection products, seeds, and merchandise products primarily in the United States, Canada, Australia, and South America, have advanced 0.72% in the last one month and 11.33% in the past three months. However, the stock has lost 9.84% in the previous one year. The company’s shares are trading above their 50-day and 200-day moving averages. Moreover, the stock’s 50-day moving average of $119.60 is greater than its 200-day moving average of $116.85. Additionally, the stock traded at a PE ratio of 17.60. The complimentary notes on AGU.TO can be accessed at: http://www.activewallst.com/registration-3/?symbol=AGU.

First Quantum Minerals (TSX: FM)

On Tuesday, shares in Vancouver, Canada based First Quantum Minerals Ltd ended the session 4.13% lower at $9.98 with a total volume of 5.14 million shares traded. Shares of First Quantum Minerals, which engages in the exploration, development, and production of mineral properties, have gained 7.66% in the last one month and 12.26% in the previous three months. However, the Company’s stock has declined 28.66% in the past one year. The stock is trading above its 50-day and 200-day moving averages. The stock’s 50-day moving average of $9.35 is greater than its 200-day moving average of $7.05. Register for free and access the latest notes on FM.TO at: http://www.activewallst.com/registration-3/?symbol=FM.

Goldcorp (TSX: G)

On Tuesday, shares in Vancouver, Canada headquartered Goldcorp Inc., which engages in the acquisition, exploration, development, and operation of precious metal properties in Canada, the United States, Mexico, and Central and South America, recorded a trading volume of 1.7 million shares, which was lower than their three months average volume of 3.6 million shares. The stock ended the day 1.23% lower at $24.83. Goldcorp Inc.’s stock has gained 8.95% in the last one month, 15.11% in the previous three months and 45.46% in the past one year. The stock is trading above its 50-day and 200-day moving averages. The company stock’s 50-day moving average of $24.00 is above its 200-day moving average of $21.30. Get free access to your notes on G.TO at: http://www.activewallst.com/registration-3/?symbol=G.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 442600

Kessler Topaz Meltzer & Check, LLC Announces Shareholder Lawsuit Filed Against Halyard Health, Inc.

RADNOR, PA / ACCESSWIRE / July 20, 2016 / The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Halyard Health, Inc. (NYSE: HYH) (“Halyard” or the “Company”) and Kimberly-Clark Corporation (“Kimberly-Clark”) (NYSE: KMB) on behalf of investors who (i) purchased or otherwise acquired Kimberly-Clark securities on or after February 25, 2013 and received Halyard securities in connection with Kimberly-Clark’s spin-off of Halyard in October 2014 and/or (ii) purchased
or otherwise acquired Halyard securities between October 21, 2014 and April 29, 2016
, inclusive (the “Class Period”).

Halyard shareholders who purchased or acquired their securities during the Class Period may, no later than August 29, 2016, petition the Court to be appointed as a lead plaintiff representative of the class.

Shareholders who wish to discuss this action or request additional information about the lawsuit are encouraged to contact Kessler Topaz Meltzer & Check attorneys D. Seamus Kaskela or Adrienne O. Bell at (888) 299-7706 or online at: https://www.ktmc.com/new-cases/halyard-health-inc#join.

Halyard provides health and healthcare supplies and solutions worldwide. Prior to October 2014, Halyard was the Health Care operating segment of Kimberly-Clark, a manufacturer of personal care, consumer tissue, and professional products. In October 2014, Halyard was spun out of Kimberly-Clark, with Kimberly-Clark shareholders receiving one share of Halyard stock for every eight shares of Kimberly-Clark stock they owned as of October 23, 2014.

The complaint alleges that the defendants made materially false and misleading statements about Halyard’s business, operations and compliance policies. Specifically, the complaint alleges that the defendants made false and/or misleading statements and/or failed to disclose that: (i) Halyard’s MICROCOOL surgical gowns consistently failed effectiveness tests and failed to meet industry standards; (ii) Kimberly-Clark and Halyard knowingly provided defective MICROCOOL surgical gowns to U.S. workers during the Ebola crisis; and (iii) as a result of the foregoing, the defendants’ public statements were materially false and misleading at all relevant times.

According to the complaint, on May 1, 2016, 60 Minutes reported that Kimberly-Clark and Halyard knowingly provided defective surgical gowns to U.S. workers at the height of the Ebola crisis. As reported, a Halyard insider claimed that although Halyard’s MICROCOOL surgical gowns were prone to leaks and did not consistently meet the industry safety standards for the treatment of Ebola, Kimberly-Clark and Halyard nonetheless “aggressively” marketed the MICROCOOL gowns to hospitals during the Ebola epidemic.

Following this news, shares of Halyard’s stock declined $1.21 per share, or 4.3%, to close on May 2, 2016 at $26.95 per share, on heavy trading volume.

Halyard shareholders may, no
later than August 29, 2016
, petition the Court to be appointed as a lead plaintiff of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, or for additional information about participating in this action, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
D. Seamus Kaskela, Esq.
Adrienne O. Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(888) 299-7706
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 442395